# Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01462929** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 414 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Aclidinium bromide
- **DRUG:** Tiotropium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01462929
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-03
- **Final completion:** 2012-05
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2017-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462929, "Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01462929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*